Biointron x Antibody Society Webinar: Developability Assessment: Why, What, and How.

When

October 23, 2025, 11:00 AM Eastern

Watch the recording here >>

About

Developability is an increasingly critical concept in antibody discovery and development. Previously associated with late-stage outcomes such as stability and formulation, developability assessment is now integrated earlier in the discovery process to enable multidimensional profiling of lead candidates.

Watch the recording here >>

Seminar Objectives

• How developability guides real-world projects. From optimizing machine learning algorithms with AI to enabling stability-driven antibody engineering, developability insights are becoming deeply embedded in discovery workflows. As our understanding evolves, so too will its role in shaping the future of drug development.

• Why developability assessments are essential at multiple stages. As biologics grow more complex, early evaluation is key to identifying promising leads. Evidence shows clear correlations between developability parameters and pharmacokinetic (PK) behavior.

• What developability entails. It refers to key biophysical properties such as hydrophobicity, thermal stability, colloidal stability, non-specific binding, and surface charge that collectively inform candidate viability. Our comprehensive assessments complement functional data to support lead selection.

Watch the recording here >>

About the Speaker

Brady Wu, PhD, Head of Protein Center at Biointron

Dr. Brady Wu is a multidisciplinary scientist and biotech leader. He holds a Ph.D. in Chemistry from The Ohio State University (2007–2013), where he pioneered solid-state NMR studies of amyloid fibril dynamics, and a Peking University honors B.S. in Biology (2003–2007). At GenScript (2013–2021), he led 100+ teams in recombinant protein production service and global project management. As the Founding CEO of Solvo Biotherapeutics (2022–2024), he built China’s top cell-free protein synthesis platform with a 15+ team. Now leading the Protein Science group at Biointron (2024–present), he drives ADC conjugation, developability assessment, and recombinant protein/antibody R&D efforts in the company.

Watch the recording here >>